Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (191-200 of 255) with videos related to

Pageof 26
Sort By:
Breast Cancer Research and Treatment|August 6, 2025
Do regularly scheduled visits result in earlier detection of curable breast cancer recurrences?Ana-Alicia Beltran-Bless, Igor de Lima Machada, Lucas Clemons, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitorsPier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.
European Urology|July 19, 2018
Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective TrialLaurence Klotz, Andrew Loblaw, Linda Sugar, et al.
Journal of the American Society of Nephrology : JASN|April 19, 2002
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal diseaseSandro Rossetti, Sarah Burton, Lana Strmecki, et al.
Investigational New Drugs|November 27, 2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckPatricia A Tang, Lillian L Siu, Eric X Chen, et al.
International Journal of Molecular Sciences|November 25, 2023
Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active SurveillanceElham Ahmadi, Simon Wang, Mohammad Gouran-Savadkoohi, et al.
Clinical Lung Cancer|November 5, 2003
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancerNatasha B Leighl, Ronald L Burkes, Janet E Dancey, et al.
Breast Cancer Research and Treatment|June 14, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyMark J Clemons, Brandy Cochrane, Gregory R Pond, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2022
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast CancerKeying Xu, Jane Bayani, Elizabeth Mallon, et al.
Breast Cancer Research and Treatment|July 31, 2024
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancerArif Ali Awan, Carol Stober, Gregory R Pond, et al.
Pageof 26

Showing results (191-200 of 255) with videos related to

Sort By:
Pageof 26
Breast Cancer Research and Treatment|August 6, 2025
Do regularly scheduled visits result in earlier detection of curable breast cancer recurrences?Ana-Alicia Beltran-Bless, Igor de Lima Machada, Lucas Clemons, et al.
Journal for Immunotherapy of Cancer|April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitorsPier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.
European Urology|July 19, 2018
Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective TrialLaurence Klotz, Andrew Loblaw, Linda Sugar, et al.
Journal of the American Society of Nephrology : JASN|April 19, 2002
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal diseaseSandro Rossetti, Sarah Burton, Lana Strmecki, et al.
Investigational New Drugs|November 27, 2007
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neckPatricia A Tang, Lillian L Siu, Eric X Chen, et al.
International Journal of Molecular Sciences|November 25, 2023
Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active SurveillanceElham Ahmadi, Simon Wang, Mohammad Gouran-Savadkoohi, et al.
Clinical Lung Cancer|November 5, 2003
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancerNatasha B Leighl, Ronald L Burkes, Janet E Dancey, et al.
Breast Cancer Research and Treatment|June 14, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyMark J Clemons, Brandy Cochrane, Gregory R Pond, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2022
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast CancerKeying Xu, Jane Bayani, Elizabeth Mallon, et al.
Breast Cancer Research and Treatment|July 31, 2024
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancerArif Ali Awan, Carol Stober, Gregory R Pond, et al.
Pageof 26